A separate analysis of the real-world trial found that those who switched from daily antiretroviral treatment to Cabenuva had fewer concerns about treatment.

A larger role for China, perhaps, and the fraught issue of integrating HIV services into services for other diseases.

According to experts at the IAS 2025 meeting in Kigali, Rwanda, AI revolutionizes HIV vaccine development by enhancing design ...

Despite the recent approval of lenacapavir as a twice yearly PrEP, there is still a need for choice in HIV prevention, argue ...

The FDA approval of lenacapavir as a form of preexposure prophylaxis (PrEP) is a major step for HIV prevention, but its ...

Experts, such as Lloyd Mulenga, M.Sc., M.B., Ch.B., Ph.D., discuss long-acting injectable HIV PrEP's potential in Zambia, ...

Investigational interstitial lung disease (ILD) drug, efzofitimod, shows early signs of efficacy in patients with pulmonary ...

Managed Healthcare Executive gives C-suite executives in health plans and provider organizations news and strategies for ...

An expert discusses how adding an anti-CD38 antibody to a triplet backbone improved minimal residual disease (MRD) negativity and progression-free survival (PFS) in frail, transplant-ineligible ...

As expected, the new recommendations that the World Health Organization (WHO) issued for HIV and sexually transmitted ...

Alarice Marsh, M.P.H., a deputy director in the National Department of Health of South Africa and program lead of HIV testing ...

Leqselvi (deuruxolitinib) 8 mg tablets are approved for adults with severe alopecia areata, a disease that causes the immune system to attack hair follicles, leading to partial or complete hair loss ...